Andembry
CSL Behring’s angioedema treatments receives NICE recommendation
September 26, 2025Regulatory Affairs, Research and Development Andembry, CSL Behring, hereditary angioedema
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
